Celgene

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Celgene and buy or sell other stocks, ETFs, and their options commission-free!

About CELG

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. 

CEO
Mark J. Alles
CEOMark J. Alles
Employees
Employees
Headquarters
Summit, New Jersey
HeadquartersSummit, New Jersey
Founded
1986
Founded1986
Employees
Employees

CELG Key Statistics

Market cap
77.04B
Market cap77.04B
Price-Earnings ratio
13.32
Price-Earnings ratio13.32
Dividend yield
Dividend yield
Average volume
27.24M
Average volume27.24M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$110.70
52 Week high$110.70
52 Week low
$58.59
52 Week low$58.59

Stock Snapshot

As of today, Celgene(CELG) shares are valued at $108.24. The company's market cap stands at 77.04B, with a P/E ratio of 13.32.

During the trading day, Celgene(CELG) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for Celgene(CELG) stock has reached 0, versus its average volume of 27.24M.

The stock's 52-week range extends from a low of $58.59 to a high of $110.70.

The stock's 52-week range extends from a low of $58.59 to a high of $110.70.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.